Prescribing Practices and Barriers of Biologics for Chronic Rhinosinusitis Amongst Otolaryngologists

Abstract

Objective(s)Biologics for chronic rhinosinusitis with nasal polyposis (CRSwNP) are an evolving therapeutic option, but there are limited data on physician experiences in prescribing them. The goal of this study was to gain a better understanding of these experiences including prescribing practices, patient factors which guide prescriber decision, and physician and patient‐reported issues which might limit cost‐effectiveness of these therapies.MethodsA survey was distributed to attending otolaryngologists using the Canadian Society of Otolaryngology (CSOHNS) email distribution and eSurvey program. Responses were tabulated for the entire cohort and compared between rhinologists and non‐rhinologists where appropriate. Frequencies and proportions were expressed as a percentage of total respondents. Fisher's exact test was used for statistical analysis between groups.ResultsSeventy‐nine total survey responses were recorded representing a response rate of 43%. Significantly more rhinologists reported prescribing biologic medications on their own (100% vs. 50%; p < 0.001) and a higher proportion (1 to 10% vs. <1%) of their patients were on biologics compared with non‐rhinologists (p = 0.023). Rhinologists were more likely to consider poor response to medical therapies, need for rescue steroids, and comorbid type 2 conditions in their decision to pursue biologics than non‐rhinologists, but they also experienced poorer assistance from patient support programs and less availability to medications.ConclusionRhinologists are more comfortable with prescribing and managing biologics for CRSwNP compared with non‐rhinologist colleagues. Clinicians prescribing biologic medications for CRSwNP should be familiar with guidelines, indications, and potential adverse events.Level of EvidenceN/A Laryngoscope, 2024